Vol 7, No 5 (October 18, 2018): Translational Lung Cancer Research (Malignant Pleural and Peritoneal Mesothelioma)

Preface

Malignant pleural and peritoneal mesothelioma: clinical update 2018
Paul Van Schil, Jan Van Meerbeeck
Translational Lung Cancer Research  
2018;
7
(5)
:505-506
.
 (18 October 2018) 
PDF Full Text (1615) Open Access Get Permission

Original Article

The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey
Youssef Ben Bouazza, Jan P. Van Meerbeeck
Translational Lung Cancer Research  
2018;
7
(5)
:507-515
.
 (18 October 2018) 
PDF Full Text (2557) Open Access Get Permission

Review Article

Hotspots of malignant pleural mesothelioma in Western Europe
Valerie Nuyts, Tim Nawrot, Benoit Nemery, Kristiaan Nackaerts
Translational Lung Cancer Research  
2018;
7
(5)
:516-519
.
 (18 October 2018) 
PDF Full Text (3339) Open Access Get Permission
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review
Lisa Brusselmans, Lieselot Arnouts, Charissa Millevert, Joyce Vandersnickt, Jan P. van Meerbeeck, Kevin Lamote
Translational Lung Cancer Research  
2018;
7
(5)
:520-536
.
 (18 October 2018) 
PDF Full Text (3913) Open Access Get Permission
Malignant peritoneal mesothelioma: a review
Glenn Broeckx, Patrick Pauwels
Translational Lung Cancer Research  
2018;
7
(5)
:537-542
.
 (18 October 2018) 
PDF Full Text (6884) Open Access Get Permission
The eighth TNM classification for malignant pleural mesothelioma
Lawek Berzenji, Paul E. Van Schil, Laurens Carp
Translational Lung Cancer Research  
2018;
7
(5)
:543-549
.
 (18 October 2018) 
PDF Full Text (12062) Open Access Get Permission
Extrapleural pneumonectomy: still indicated?
Andreas Domen, Lawek Berzenji, Jeroen M. H. Hendriks, Suresh Krishan Yogeswaran, Patrick Lauwers, Jan P. Van Meerbeeck, Paul E. Van Schil
Translational Lung Cancer Research  
2018;
7
(5)
:550-555
.
 (18 October 2018) 
PDF Full Text (4301) Open Access Get Permission
Extended pleurectomy decortication: the current role
Rocco Bilancia, Marco Nardini, David A. Waller
Translational Lung Cancer Research  
2018;
7
(5)
:556-561
.
 (18 October 2018) 
PDF Full Text (4757) Open Access Get Permission
Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations
Charlotte De Bondt, Ioannis Psallidas, Paul E. Y. Van Schil, Jan P. van Meerbeeck
Translational Lung Cancer Research  
2018;
7
(5)
:562-573
.
 (18 October 2018) 
PDF Full Text (2637) Open Access Get Permission
Current chemotherapy strategies in malignant pleural mesothelioma
Cornedine Jannette de Gooijer, Paul Baas, Jacobus Adrianus Burgers
Translational Lung Cancer Research  
2018;
7
(5)
:574-583
.
 (18 October 2018) 
PDF Full Text (6270) Open Access Get Permission
Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?
Paul Halford, Amelia O. Clive
Translational Lung Cancer Research  
2018;
7
(5)
:584-592
.
 (18 October 2018) 
PDF Full Text (2042) Open Access Get Permission
A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205)
Jo Raskin, Veerle Surmont, Robin Cornelissen, Paul Baas, Paul E. Y. van Schil, Jan P. van Meerbeeck
Translational Lung Cancer Research  
2018;
7
(5)
:593-598
.
 (18 October 2018) 
PDF Full Text (2804) Open Access Get Permission
Update on the management of malignant peritoneal mesothelioma
Paul H. Sugarbaker
Translational Lung Cancer Research  
2018;
7
(5)
:599-608
.
 (18 October 2018) 
PDF Full Text (9298) Open Access Get Permission

News

Translational Lung Cancer Research, the 7th AME Journal indexed in SCIE
Editorial Office
Translational Lung Cancer Research  
2018;
7
(5)
:609-613
.
 (18 October 2018) 
PDF Full Text (1791) Open Access Get Permission

Disclosure:

The focused issue “Malignant Pleural and Peritoneal Mesothelioma” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Paul Van Schil and Jan Van Meerbeeck served as the unpaid Guest Editors for the focused issue.